Related Experiment Video

Updated: Jul 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Therapeutic platforms for cancer management centered on blocking the PD-L1/PD-1 interaction through the use of

Abolfazl Marvizadeh1, Elham Sameiyan2, Amir Teymour Najjarkar1

  • 1Student Research Committee, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran.

International Journal of Biological Macromolecules
|July 13, 2026
PubMed

Insights

Aptamers offer a novel strategy to block the PD-1/PD-L1 pathway in cancer immunotherapy, potentially overcoming resistance and improving treatment outcomes.

Area of Science:

  • Immunology
  • Biotechnology
  • Oncology

Background:

  • The PD-1/PD-L1 pathway is a key target in cancer immunotherapy, but challenges like resistance and side effects persist.
  • Novel strategies are needed to enhance the efficacy and accessibility of PD-1/PD-L1 blockade therapies.

Purpose of the Study:

  • To review aptamer-based strategies for inhibiting the PD-1/PD-L1 immune checkpoint pathway.
  • To evaluate the potential of aptamers in overcoming current limitations of PD-1/PD-L1 blockade.

Main Methods:

  • Comprehensive literature review of aptamer design and application targeting PD-1/PD-L1.
  • Analysis of recent advances in aptamer-driven cancer immunotherapy.

Main Results:

  • Aptamers demonstrate high affinity and specificity for PD-1 and PD-L1, offering an alternative to antibodies.
  • Aptamer-based strategies show promise in enhancing antitumor immune responses.
  • Aptamers may address challenges like therapeutic resistance and treatment costs.

Conclusions:

  • Aptamers represent a promising therapeutic modality for targeting the PD-1/PD-L1 pathway in cancer.
  • Further research into aptamer development can optimize cancer immunotherapy and clinical outcomes.
Keywords:
AptamerImmunotherapyPD-L1/PD-1

More Related Videos

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...